Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis

By sjmartinez • September 22, 2023

Chen DH, Lenz HJ, Lechner MG, Angell TE. Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis. AACE Clin Case Rep. 2023 Jun 3;9(5):162-165. doi: 10.1016/j.aace.2023.05.009. PMID: 37736314; PMCID: PMC10509378.

Tags: efficacy, Endocrinology, immune checkpoint inhibitors, immune-related adverse events, papillary thyroid carcinoma, Publications, thyroiditis

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas

Raverot G, Burman P, Abreu AP, Heaney AP, van Hulsteijn L, Lin AL, Marcus H, McCormack A, Minniti G, Petersenn S, Popovic V, Theodoropoulou M,[...]

Specific imaging features of sellar atypical teratoid/rhabdoid tumor or the lack of thereof

Yu R. Specific imaging features of sellar atypical teratoid/rhabdoid tumor or the lack of thereof. World J Radiol. 2025 May 28;17(5):106975. doi: 10.4329/wjr.v17.i5.106975. PMID: 40503480;[...]

Importance of symptoms acuity for clinical diagnosis of primary sellar atypical teratoid/rhabdoid tumor

Yu R. Importance of symptoms acuity for clinical diagnosis of primary sellar atypical teratoid/rhabdoid tumor. World J Clin Oncol. 2025 May 24;16(5):106292. doi: 10.5306/wjco.v16.i5.106292. PMID:[...]